Immunohistology of Lung and Pleural Neoplasms

Diagnostic Immunohistochemistry

Volumn , Issue , 2011, Pages 369-463

  Hammar, Samuel P ^a,b   Dacic, Sanja ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Diagnostic Specialties Laboratory Inc   (United States)

^c PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649917329     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5766-6.00016-9     Document Type: Chapter

References (539)

1. Han H., Landreneaux R.J., Santucci T.S., et al. Prognostic value of immunohistochemical expression of p53, HER-2-neu and bcl-2 in stage I non-small cell lung cancer. Hum Pathol 2002, 33:105-110.
2. Minami K., Saito Y., Imamura H. Okamura. Prognostic significance of p53, Ki67, VEGF and GLUT-1 in resected stage I adenocarcinoma of the lung. Lung Cancer 2002, 38:51-57.
3. Nakanishi K., Kawai T., Kumaki F., et al. Survivin expression in atypical adenomatous hyperplasia of the lung. Am J Clin Pathol 2003, 120:712-719.
4. Yamaguchi N.H., Lichetenfels A.J., Demarchi L.M.M., et al. Cox-2, MMP-9 and Noguchi classification provide additional prognostic information about adenocarcinomas of the lung: A study of 117 patients from Brazil. Am J Clin Pathol 2004, 121:78-86.
5. Saad R.S., Liu Y., Han H., et al. Prognostic significance of HER2/neu, p53 and vascular endothelial growth factor expression in early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Mod Pathol 2004, 17:1234-1242.
6. Pelosi G., Pasini F., Fraggetta F., et al. Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids. Lung Cancer 2003, 42:203-213.
7. Pelosi G., Pastorini O., Pasini F., et al. Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. Br J Cancer 2003, 88:537-547.
8. Jagirdar J. Immunohistochemistry: Then and Now. Arch. Pathol Lab Med 2008, 132:323-325.
9. Hammar S.P. Common neoplasms. Pulmonary Pathology 1994:, 1487-1579. Springer-Verlag, New York. 2nd ed. D.H. Dail, S.P. Hammar (Eds.).
10. Dodds L., Davis S., Polissar L. A population-based study of lung cancer incidence by histological type. J Natl Cancer Inst 1986, 76:21-29.
11. Thun M.J., Lally C.A., Flannery J.T., et al. Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 1997, 89:1580-1586.
12. Moll R., Franke W.W., Schiller D.L., et al. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982, 31:11-24.
13. Moll R., Lowe A., Laufer J., et al. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Surg Pathol 1992, 140:427-447.
14. Ramaekers F., Huysmans A., Schaart G., et al. Tissue distribution of keratin 7 as monitored by a monoclonal antibody. Exp Cell Research 1987, 170:235-249.
15. Chu P., Wu E., Weiss L.M. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases. Mod Pathol 2000, 13:962-972.
16. Hammar S.P., Hallman K.O. Unusual primary lung neoplasms: spindle cell and undifferentiated carcinomas expressing only vimentin. Ultrastruct Pathol 1990, 14:407-422.
17. Upton M.P., Hirohashi S., Tome Y., et al. Expression of vimentin in surgically resected adenocarcinomas and large cell carcinomas of lung. Am J Surg Pathol 1986, 10:560-567.
18. Guazzi S., Price M., DeFelice M., et al. Thyroid nuclear factor-1 (TTF-1) contains a homeodomain and displays a novel DNA-binding specificity. EMBO J 1990, 9:3631-3639.
19. Lazzaro D., Price M., DeFelice M., et al. The transcription factor TTF-1 expressed at the onset of thyroid and lung morphogenesis and in the restricted regions of the foetal brain. Development 1991, 113:1093-1094.
20. Bohinski R.J., DiLauro R., Whitsett J.A. The lung specific surfactant protein B promoter is a target for thyroid transcription factor-1 and hepatocyte nuclear factor 3, indicating common factors for organ-specific gene expression along the Foregut axis. Mol Cell Biol 1994, 14:5671-5678.
21. Bohinski R.J., Huffman J.A., Whitsett J.A., et al. Cis-active elements controlling lung cell-specific expression of human pulmonary surfactant B gene. J Biol Chem 1993, 268:11160-11166.
22. Bejarano P.A., Baughman R.P., Biddinger P.W., et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol 1996, 9:445-452.
23. Fabbro D., DiLoreto C., Stamerra O., et al. TTF-1 gene expression in human lung tumors. Eur J Cancer 1996, 32A:512-573.
24. DiLoreto C., DiLauro V., Puglisi F., et al. Immunohistochemical expression of tissue specific transcription factor-1 in lung carcinoma. J Clin Pathol 1997, 50:30-32.
25. Holzinger A., Dingle S., Bejarano P.A., et al. Monoclonal antibody to thyroid transcription factor-1: Production, characterization and usefulness in tumor diagnosis. Hybridoma 1996, 15:49-53.
26. Folpe A.L., Gown A.M., Lamps L.W., et al. Thyroid transcription factor-1: Immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol 1999, 12:5-8.
27. Au N.H.C., Gown A.M., Cheang M., et al. p63 expression in lung carcinomas: A tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 2004, 12:240-247.
28. Sheikh H.A., Fuhrer K., Cieply K., et al. p63 expression in assessment of bronchioloalveolar proliferations of the lung. Mod Pathol 2004, 17:1134-1140.
29. Hammar S.P. Metastatic adenocarcinoma of unknown primary origin. Hum Pathol 1998, 29:1393-1402.
30. Amin M.B., Tamboli P., Merchant S.H. Micropapillary component in lung adenocarcinoma: A distinctive histologic feature with possible prognostic significance. Am J Surg Pathol 2002, 26:358-364.
31. Nakamura N., Miyagi E., Murata S., et al. Expression of thyroid transcription factor-1 in normal and neoplastic lung tissues. Mod Pathol 2002, 15:1058-1067.
32. Lau S.K., Desrochers M.J., Luthringer D.J. Expression of thyroid transcription factor-1, cytokeratin 7 and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases. Mod Pathol 2002, 15:538-542.
33. Simsir A., Wei X.J., Yee H., et al. Differential expression of cytokeratins 7 and 20 and thyroid transcription factor-1 in bronchioloalveolar carcinoma: an immunohistochemical study in fine needle aspiration biopsy specimens. Am J Clin Pathol 2004, 121:350-357.
34. Johansson L. Histopathologic classification of lung cancer: relevance of cytokeratin and TTF-1 immunophenotyping. Ann Diagn Pathol 2004, 8:259-267.
35. Yatabe Y., Mitsudomi T., Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 2002, 26:767-773.
36. Chang Y., Lee Y., Lia W., et al. The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. Lung Cancer 2004, 44:149-157.
37. Saad R.S., Liu Y.L., Han H., et al. Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Hum Pathol 2004, 35:3-7.
38. Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med 2008, 132:384-396.
39. Sainz I.M., Fukuoka J., Cagle P.T., et al. A new marker for lung adenocarcinoma is complementary and more sensitive than TTF-1 (thyroid transcription factor-1): Evaluation of 967 cases by tissue microarray. Mod Pathol 2008, 21:349A.
40. Yesner R. Small cell tumors of the lung. Am J Surg Pathol 1983, 7:775-785.
41. Carter D. Small-cell carcinoma of the lung. Am J Surg Pathol 1983, 7:787-795.
42. Yesner R. Classification of lung cancer histology. N Engl J Med 1985, 312:652-653.
43. Arrigoni M.G., Woolner L.B., Berantz P.E. Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg 1972, 64:413-421.
44. Leschke H. Über nur regionär bösartige und über krebsig entartete Bronchusadenome bzw. Carcinoide. Virch Arch [Pathol Anat] 1956, 328:635-657.
45. Warren W.H., Memoli V.A., Gould V.E. Immunohistochemical and ultrastructural analysis of bronchopulmonary neuroendocrine neoplasms: II. Well-differentiated neuroendocrine carcinomas. Ultrastruct Pathol 1984, 7:185-199.
46. Mark E.J., Ramirerz J.F. Peripheral small-cell carcinoma of the lung resembling carcinoid tumor: A clinical and pathologic study of 14 cases. Arch Pathol Lab Med 1985, 109:263-269.
47. Paladugu R.R., Benfield J.R., Pak H.Y., et al. Bronchopulmonary Kulchitzky cell carcinomas. Cancer 1985, 55:1303-1311.
48. Travis W.D., Colby T.V., Corrin B., et al. Histological Typing of Lung and Pleural Tumors 1999, Springer-Verlag, New York.
49. Thomas C.F., Tazelaar H.D., Jett J.R. Typical and atypical pulmonary carcinoids: Outcome in patients presenting with regional lymph node involvement. Chest 2001, 119:1143-1150.
50. Slodkowska J., Langfort R., Rudzinski P., et al. Typical and atypical pulmonary carcinoids-Pathologic and clinical analysis of 77 cases. Pneumonol Alergol Pol 1998, 66:297-303.
51. Gould V.E., Chejfec G. Ultrastructural and biochemical analysis of pulmonary "undifferentiated" carcinomas. Hum Pathol 1978, 9:377-384.
52. Hammond M.E., Sause W.T. Large cell neuroendocrine tumors of the lung: Clinical significance and histological definition. Cancer 1985, 56:1624-1629.
53. Neal M.H., Kosinki R., Cohen P., et al. Atypical endocrine tumors of the lung: A histologic, ultrastructural and clinical study of 19 cases. Hum Pathol 1986, 17:1264-1277.
54. Barbareschi M., Mariscotti C., Barberis M., et al. Large cell neuroendocrine of the lung. Tumor 1989, 75:583-588.
55. McDowell E.M., Wilson T.S., Trump B.F. Atypical endocrine tumors of the lung. Arch Pathol Lab Med 1981, 105:20-28.
56. Travis W.D., Linnoila I., Tsokos M.G., et al. Neuroendocrine tumors of the lung with proposed criteria for large cell neuroendocrine carcinoma: An ultrastructural, immunohistochemical and flow cytometric study of 35 cases. Am J Surg Pathol 1991, 15:529-533.
57. Hammar S., Bockus D., Remington F., Cooper L. The unusual spectrum of neuroendocrine lung neoplasms. Ultra Pathol 1989, 13:515-560.
58. Jiang S.X., Kameya T., Shoji M., et al. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases. Am J Surg Pathol 1998, 22:526-537.
59. Sturm N., Lantuejoul S., Laverriere M.H., et al. Thyroid transcription factor-1 and cytokeratins 1, 5, 10, 14 (34βE12) expression in basaloid and large cell neuroendocrine carcinomas of the lung. Hum Pathol 2001, 32:918-925.
60. Jung K.J., Lee K.S., Han J., et al. Large cell neuroendocrine carcinoma of the lung: Clinical, CT and pathologic findings in 11 patients. J Thorac Imaging 2001, 16:156-162.
61. Mazieres J., Daste G., Molinier L., et al. Large cell neuroendocrine carcinoma of the lung: pathological study and clinical outcome of 18 resected cases. Lung Cancer 2002, 37:287-292.
62. Paci M., Cavazza A., Annessi V., et al. Large cell neuroendocrine carcinoma of the lung: A 10 year clinicopathologic retrospective study. Ann Thorac Surg 2004, 77:1163-1167.
63. Doddoli C., Barlesi F., Chetaille B., et al. Large cell neuroendocrine carcinoma of the lung: An aggressive disease potentially treatable with surgery. Ann Thorac Surg 2004, 77:1168-1172.
64. Peng W.X., Sano T., Oyama T., et al. Large cell neuroendocrine carcinoma of the lung: A comparison with large cell carcinoma with neuroendocrine morphology and small cell carcinoma. Lung Cancer 2005, 47:225-233.
65. Pearse A.G.E. The diffuse neuroendocrine system: An extension of the APUD concept. Endocrinology 1972, 145-222. Heinemann, London. S. Taylor (Ed.).
66. Gould V.E., DeLellis R.A. The neuroendocrine cell system: Its tumors, hyperplasias and dysplasias. Principles and practice of surgical pathology 1983, 1488-1501. John Wiley, New York. S.G. Silverberg (Ed.).
67. Hammar S.P., Gould V.E. Neuroendocrine neoplasms. Pathology of Human Neoplasms: An Atlas of Diagnostic Electron Microscopy and Immunohistochemistry 1988, 333-404. Raven Press, New York. H.A. Azar (Ed.).
68. Jahn B., Schibler W., Ouimet C., et al. A 38,000 dalton membrane protein (p38) present in synaptic vesicles. Proc Natl Acad Sci USA 1985, 82:4137-4141.
69. Wiedenmann B., Franke W.W. Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell 1985, 41:1017-1028.
70. Carmichael S.W., Winkler H. The adrenal chromaffin cell. Sci Am 1985, 253:40-49.
71. O'Connor D.T., Frigon R.P. Chromogranin A, the major catecholamine storage vesicle protein. J Biol Chem 1984, 259:3237-3247.
72. Banks P., Helle K. The release of protein from the stimulated adrenal medulla. Biochem J 1965, 97:40C-41C.
73. Haimoto H., Takahashi V., Koshikawa T., et al. Immunohistochemical localization of gamma-enolase in normal human tissues other than nervous and neuroendocrine tissues. Lab Invest 1985, 52:257-263.
74. Pahlman S., Esscher T., Nilsson K. Expression of gamma-subunit of enolase, neuron-specific enolase in human non-neuroendocrine tumors and derived cell lines. Lab Invest 1986, 54:554-560.
75. Leoncini P., DeMarco E.B., Bognoli M., et al. Expression of phosphorylated and non-phosphorylated neurofilament subunits and cytokeratins in neuroendocrine lung tumors. Pathol Res Pract 1989, 185:848-855.
76. Komminoth P., Roth J., Lackie P.M., et al. Polysialic acid of the neural cell adhesion molecule distinguishes small cell carcinoma from carcinoids. Am J Pathol 1991, 139:297-304.
77. Kibbelaar R.E., Moolenaar C.E.C., Michalides R.J.A.M., et al. Expression of the embryonal neural cell adhesion molecule N-CAM in lung carcinoma: Diagnostic usefulness of monoclonal antibody 735 for the distinction between small cell lung cancer and non-small cell lung cancer. J Pathol 1989, 159:23-28.
78. Bunn P., Linnoila I., Minna J., et al. Small-cell lung cancer, endocrine cells of the fetal bronchus and other neuroendocrine cells express Leu-7 antigenic determinant present on natural killer cells. Blood 1985, 65:764-768.
79. Matsuki Y., Tanimoto A., Hamada T., et al. Histidine decarboxylase expression as a new sensitive and specific marker for small cell lung carcinoma. Mod Pathol 2003, 16:72-78.
80. Gibbs A.R., Whimster W.F. Tumors of the lung and pleura. Diagnostic Histopathology of Tumors 1995, 127-150. Churchill Livingstone, Edinburg. C.D.M. Fletcher (Ed.).
81. Dail D.H. Uncommon neoplasms. Pulmonary Pathology 1994, 1279-1461. Springer-Verlag, New York. 2nd ed. D.H. Dail, S.P. Hammar (Eds.).
82. Wick M.R., Swanson P.E. Carcinosarcomas: current perspective and a historical review of nosologic concepts. Semin Diag Pathol 1993, 10:118-127.
83. Addis B.J., Corrin B. Pulmonary blastoma, carcinosarcoma and spindle cell carcinoma: An immunohistochemical study of keratin intermediate filaments. J Pathol 1985, 147:291-301.
84. Zarbo R.J., Crissman J.D., Venkat H., et al. Spindle cell carcinoma of the upper aerodigestive tract mucosa: An immunohistologic and ultrastructural study of 18 biphasic tumors and comparison with seven monophasic spindle cell tumors. Am J Surg Pathol 1986, 10:741-753.
85. Humphrey P.A., Scroggs M.W., Roggli V.L., et al. Pulmonary carcinomas with a sarcomatoid element: An immunohistochemical and ultrastructural analysis. Hum Pathol 1988, 19:155-165.
86. Colby T.V., Bilbao J.E., Battifora H., et al. Primary osteosarcoma of the lung: A re-appraisal following immunohistologic study. Arch Pathol Lab Med 1989, 113:1147-1150.
87. Nappi O., Glasner S.D., Swanson P.E., et al. Biphasic and monophasic sarcomatoid carcinomas of the lung: A re-appraisal of "carcinosarcomas" and "spindle cell carcinomas.". Am J Clin Pathol 1994, 102:331-340.
88. Fishback N.F., Travis W.D., Moran C.A., et al. Pleomorphic (spindle/giant cell) carcinoma of the lung. Cancer 1994, 73:2936-2945.
89. Pelosi G., Fraggetta F., Nappi O., et al. Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth and tumor cell motility: A clinicopathologic and immunohistochemical study of 31 cases. Am J Surg Pathol 2003, 27:1203-1215.
90. Koss M.N., Hochholzer L., O'Leary T. Pulmonary blastomas. Cancer 1983, 73:265-294.
91. Yousem S.A., Wick M.R., Randhawa P., et al. Pulmonary blastoma: An immunohistochemical analysis and comparison with fetal lung in its pseudoglandular stage. Am J Clin Pathol 1990, 93:167-175.
92. Etienne-Mastroianni B., Falchero L., Chalabreysse L., et al. Primary sarcomas of the lung: A clinicopathologic study of 12 cases. Lung Cancer 2002, 38:283-290.
93. Ognibene F.P., Steis R.G., Macher A.M., et al. Kaposi's sarcoma causing pulmonary infiltrates and respiratory failure in the acquired immunodeficiency syndrome. Ann Intern Med 1985, 102:471-475.
94. Garay S.M., Belenko M., Fazzini E., et al. Pulmonary manifestations of Kaposi's sarcoma. Chest 1987, 91:39-43.
95. White D.A., Matthay R.A. Noninfectious pulmonary complications of infection with the human immunodeficiency virus. Am Rev Respir Dis 1989, 140:1763-1787.
96. McLoud T.C., Naidich D.P. Thoracic disease in the immunocompromised patient. Radiol Clin North Am 1992, 30:525-554.
97. Ognibene F.P., Shelhamer J.H. Kaposi's sarcoma. Clin Chest Med 1988, 9:459-465.
98. Heitzman E.R. Pulmonary neoplastic lymphoproliferative disease in AIDS: A review. Radiology 1990, 177:347-351.
99. Purdy L.J., Colby T.V., Yousem S.A., et al. Pulmonary Kaposi's sarcoma. Premortem histologic diagnosis. Am J Surg Pathol 1986, 10:301-311.
100. Hymes K.B., Cheung T., Greene J.B., et al. Kaposi's sarcoma in homosexual men: A report of eight cases. Lancet 1981, 2:598-600.
101. Kaposi's sarcoma and pneumocystis pneumonia in homosexual men-New York City and California. MMWR 1981, 30:305-308.
102. Gottlieb G.J., Ackerman A.B. Kaposi's sarcoma: An extensively disseminated form in young homosexual men. Hum Pathol 1982, 13:882-892.
103. Adem C., Aubry M.C., Tazelaar H.D., et al. Metastatic angiosarcoma masquerading as diffuse pulmonary hemorrhage: Clinicopathologic analysis of 7 new patients. Arch Pathol Lab Med 2001, 125:1562-1565.
104. Tschernig T., Pabst R. Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different disease. Pathobiology 2000, 68:1-8.
105. Richmond I., Pritchard G.E., Ashcroft T., et al. Bronchus associated lymphoid tissue (BALT) in human lungs: Its distribution in smokers and nonsmokers. Thorax 1993, 48:1130-1134.
106. Swigris J.J., Berry G.J., Raffin T.A., et al. Lymphoid interstitial pneumonia. A narrative review. Chest 2002, 122. 2150-1064.
107. Bienenstock J., Johnston N., Perey D.Y.E. Bronchial lymphoid tissue. I. Morphologic characteristics. Lab Invest 1973, 28:686-692.
108. Bienenstock J., Johnston N., Perey D.Y.E. Bronchial lymphoid tissue II. Functional characteristics. Lab Invest 1973, 28:693-698.
109. Pisani R.J., Witzit T.E., Li C.Y., et al. Confirmation of lymphomatous pulmonary involvement by immunophenotypic and gene rearrangement analysis of broncho-alveolar lavage fluid. Mayo Clin Proc 1990, 65:651-656.
110. Kuroso K., Yumo T., Rom W.N., et al. Oligoclonal T cell expansions in pulmonary lymphoproliferative disorders: Demonstration of the frequent occurrence of oligoclonal T cells in human Immunodeficiency virus-related lymphoid interstitial pneumonia. Am J Respir Crit Care Med 2002, 165:254-259.
111. Colby T.V. Lymphoproliferative diseases. Pulmonary Pathology Tumors 1995, 343-368. Springer Verlag, New York. D.H. Dail, S.P. Hammar, T.V. Colby (Eds.).
112. Lymphoproliferative Disorders and Leukemia. Diagnosis of Diseases of the Chest 1999, 1269-1330. Saunders, Philadelphia. 4th ed. R.S. Fraser, P.D. Pare, N.L. Muller, Colmann (Eds.).
113. Jaffe E.S., Harris N.L., Stein H., et al. Genetics of tumours of hematopoietic and lymphoid tissues 2001, IARC Press, Lyon.
114. Nicholson A.G. Lymphoproliferative lung disease. Pathology of Lung Tumors 1997, 213-223. Churchill Livingstone, New York. B. Corrin (Ed.).
115. Yousem S.A. Lung tumors in the immunocompromised host 1997, 189-212. Churchill Livingstone, New York. B. Corrin (Ed.).
116. Koss M.N. Pulmonary lymphoid disorders. Sem Diag Pathol 1995, 158-171.
117. Kradin R.L., Mark E.G. Benign lymphoid disorders of the lung with a theory regarding their development. Human Pathol 1983, 14:857-867.
118. Colby T.V. Lymphoproliferative diseases 1994, 1097-1122. Springer-Verlag, New York. 2nd ed. D.H. Dail, S.P. Hammar (Eds.).
119. Saldana M.J., Patchfsky A.S., Israel H.L., et al. Pulmonary angiitis and granulomatosis. The relationship between histologic features, organ involvement and response to treatment. Hum Pathol 1977, 8:391-409.
120. Israel H.L., Patchfsky A.S., Saldana M.J. Wegener's granulomatosis, lymphomatoid granulomatosis, and benign lymphocytic angiitis and granulomatosis of lung. Recognition and treatment. Ann Intern Med 1977, 87:691-699.
121. Jaffe E.S., Banks P.M., Natwhani B., et al. Recommendations for reporting of lymphoid neoplasms: A report from the association of directors of anatomic and surgical pathology. The ad hoc committee of reporting of lymphoid neoplasms. Hum Pathol 2002, 33:1064-1068.
122. His E.D., Yegaptan S. Lymphoma Immunophenotyping: A new era in paraffin-sectioned immunohistochemistry. Advances in Anatomic Pathology 2001, 8:218-239.
123. Rosenow C., Wilson W.R., Cockerill F.R. Pulmonary disease in the immunocompromised host. Mayo Clin Proc 1985, 60:473-487.
124. Lin Y., Rodriguez G.D., Turner J.F., et al. Plasmablastic lymphoma of the lung: Report of a unique case and review of the literature. Arch Pathol and Laboratory Medicine 2001, 125:282-285.
125. L'Hoste R.J., Filippa D.A., Lieberman P.H., et al. Primary pulmonary lymphomas: A clinicopathologic analysis of 36 cases. Cancer 1984, 54:1397-1406.
126. Radin A.I. Primary pulmonary Hodgkin's disease. Cancer 1990, 65:550-563.
127. Liebow A.A., Carrington C.B., Friedman P.J. Lymphomatoid granulomatosis. Hum Pathol 1972, 3:457-558.
128. Katzenstein A.L., Carrington C.B., Liebow A.A. Lymphomatoid granulomatosis: A clinicopathologic study of 152 cases. Cancer 1979, 43:360-373.
129. Guinee D, Kingma D, Fishback N, et al. Pulmonary lesions with features of lymphomatoid granulomatosis/angiocentric immunoproliferative lesion (LYT/AIL); evidence for Epstein-Barr virus within B lymphocytes. 1994;USCAP Abstract #881.
130. Fauci A.S., Haynes B.F., Costa J., et al. Lymphomatoid granulomatosis: Prospective, clinical and therapeutic experience over 10 years. N Engl J Med 1982, 306:68-74.
131. Demirer T., Dail D.H., Aboulafia D.M. Four varied cases of intravascular lymphomatosis and a literature review. Cancer 1994, 73:1738-1745.
132. Tan T.B., Spaander P.J., Blaisse M., et al. Angiotropic large cell lymphoma presenting as interstitial lung disease. Thorax 1988, 43:578-579.
133. Snyder L.S., Harmon K.R., Estensen R.D. Intravascular lymphomatosis (malignant angioendotheliomatosis) presenting as pulmonary hypertension. Chest 1989, 96:1199-1200.
134. Yousem S.A., Colby T.B. Intravascular lymphomatosis presenting in the lung. Cancer 1990, 65:349-353.
135. Pellicone J.T., Goldstein H.B. Pulmonary malignant angioendotheliomatosis: Presentation with fever and syndrome of inappropriate anti-diuretic hormone. Chest 1990, 98:1292-1294.
136. Takamura K., Nasuhara Y., Mishina T., et al. Intravascular lymphomatosis diagnosed by transbronchial lung biopsy. Eur Respir J 1997, 10:955-957.
137. Walls J.G., Hong Y.G., Cox J.E., et al. Pulmonary intravascular lymphomatosis: Presentation with dyspnea and air trapping. Chest 1999, 115:1207-1210.
138. Ansari M.Q., Dawson D.B., Nador R., et al. Primary body cavity-based AIDS-related lymphomas. Am J Clin Pathol 1996, 105:221-229.
139. Banks P.M., Warnke R.A. Primary effusion lymphoma. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues 2001, 179-180. IARC Press, Lyon.
140. Banks P.M., Harris N.L., Warnke R.A. Primary effusion lymphoma. WHO Classification of Tumors of the Lung, Pleura and Mediastinum 2004, IARC Press, Lyon. W.D. Travis, E. Brambilla (Eds.).
141. Cesarman E., Chang Y., Moore P.S., et al. Kaposi's sarcoma-associated herpes virus-like DNA sequencing in age-related body cavity lymphoma. N Engl J Med 1995, 332:1186-1191.
142. Aozasa K., Ohsaw A.M., Kanno H. Pyothorax-associated lymphoma: A distinctive type of lymphoma strongly associated with Epstein-Barr virus. Adv in Anat Pathol 1997, 4:58-63.
143. Gaulard P., Harris N.L. Pyothorax-associated lymphoma. WHO Classification of Tumors of the Lung, Pleura and Mediastinum 2004, IARC Press, Lyon. W.D. Travis, E. Brambilla (Eds.).
144. Ibuka T., Fukayama M., Hayashi Y., et al. Pyothorax-associated pleural lymphoma. Cancer 1994, 73:738-744.
145. Allen T.C., Barrios-Chevez P., Shetlar D.J., et al. Pulmonary and opthalmic involvement with Erdheim-Chester disease; a case report and review of the literature. Arch Pathol Lab Med 2004, 128:1428-1431.
146. Hammar S.P. Pulmonary histiocytosis-X (Langerhans cell granulomatosis). Pulmonary Pathology 1994, 567-596. Springer-Verlag, New York. 2nd ed:. D.H. Dail, S.P. Hammar (Eds.).
147. Carter D., Patchefsky A.S., Mountain C.F. Clear cell lesions. Tumors and Tumor-like Lesions of the Lung 1998, 271-274. WB Saunders, Philadelphia. D. Carter, A.S. Patchefsky (Eds.).
148. Bonetti F., Pea M., Martigoni G., et al. Clear cell ("sugar tumor") of the lung is a lesion strictly related to angiomyolipoma-the concept of a family of lesions characterized by the presence of the perivascular epithelioid cells (PEC). Pathology 1994, 26:230-236.
149. Panizo-Santos A., Sola I., de Alava E., et al. Angiomyolipoma and PEComa are immunoreactive for MyoD1 in cell cytoplasmic staining pattern. Appl Immunohistochem Mol Morphol 2003, 11:156-160.
150. Gaffey M., Mills S., Zarbo R., et al. Clear cell tumor of the lung: Immunohistochemical and ultrastructural evidence of melanogenesis. Am J Surg Pathol 1991, 15:644-653.
151. Sullivan E.J. Lymphangioleiomyomatosis: A review. Chest 1998, 114:1689-1703.
152. Johnson S. Lymphangioleiomyomatosis: Clinical features, management and basic mechanism. Thorax 1999, 54:254-264.
153. Liebow A.A., Hubbell D.S. Sclerosing hemangioma (histiocytoma, xanthoma) of the lung. Cancer 1956, 9:53-75.
154. Sogio K., Yokoyama H., Kanedo S., et al. Sclerosing hemangioma of the lung: radiographic and pathologic study. Ann Thorac Surg 1992, 53:295-300.
155. Katzenstein A.-L.A., Gmelich J.T., Carrington C.B. Sclerosing hemangioma of the lung: A clinicopathologic study of 51 cases. Am J Surg Pathol 1982, 4:343-356.
156. Devouassoux-Shisheboran M., Hayashi T., Linnoila R.I., et al. A clinicopathologic study of 100 cases of pulmonary sclerosing hemangioma with immunohistochemical studies: TTF-1 is expressed in both round and surface cells, suggesting an origin from primitive respiratory epithelium. Am J Surg Pathol 2000, 24:906-916.
157. Devouassoux-Shisheboran M., de la Fouchardiere A., Thivolet-Bejui F., et al. Endobronchial variant of sclerosing hemangioma of the lung: Histological and cytological features on endobronchial material. Mod Pathol 2004, 17:252-257.
158. Miyagawa-Hayashino A., Tazelaar H.D., Langel D.J., et al. Pulmonary sclerosing hemangioma with lymph node metastases: Report of 4 cases. Arch Pathol Lab Med 2003, 127:321-325.
159. Beckwith J.B., Palmer N.F. Histopathology and prognosis of Wilms' tumor: Results from the first national Wilms' tumor study. Cancer 1978, 55:2850-2853.
160. Small E.J., Gordon G.J., Dahms B.B. Malignant rhabdoid tumor of the heart in an infant. Cancer 1985, 55:2850-2853.
161. Balaton A.J., Vaury P., Videgrain M. Paravertebral malignant rhabdoid tumor in an adult: A case report of immunocytochemical study. Pathol Res Pract 1987, 182:713-718.
162. Harris M., Eyden B.P., Joglekar V.M. Rhabdoid tumour of the bladder: A histological, ultrastructural and immunohistochemical study. Histopathology 1987, 11:1083-1089.
163. Biggs P.J., Garren P.D., Posers J.M., et al. Malignant rhabdoid tumor of the central nervous system. Hum Pathol 1987, 18:332-337.
164. Dervan P.A., Cahalane S.F., Kneafsey P., et al. Malignant rhabdoid tumor of soft tissue: An ultrastructural and immunohistological study of a pelvic tumour. Histopathol 1987, 11:183-190.
165. Parham D.M., Peiper S., Robicheaux G., et al. Malignant rhabdoid tumor of the liver: Evidence for epithelial differentiation. Arch Pathol Lab Med 1988, 112:61-64.
166. Jakate S.M., Mardsen H.B., Ingram L. Primary rhabdoid tumour of the brain. Virch Arch [A] 1988, 412:393-397.
167. Uchida H., Yokoyama S., Nakayama I., et al. An autopsy case of malignant rhabdoid tumor arising from soft parts in the left inguinal region. Acta Pathol Jpn 1988, 38:1087-1096.
168. Patron M., Palacious J., Rodriguez-Peralto J.L., et al. Malignant rhabdoid tumor of the tongue: A case report with immunohistochemical and ultrastructural findings. Oral Surg Oral Med Oral Path 1988, 65:67-70.
169. Carter R.L., McCarthy K.P., al-Sam S.Z., et al. Malignant rhabdoid tumour of the bladder with immunohistochemical and ultrastructural evidence suggesting histiocytic origin. Histopathology 1989, 14:179-190.
170. Jsujimura T., Wasa A., Kawano K., et al. A case of malignant rhabdoid tumor arising from soft parts of the prepubic region. Acta Pathol Jpn 1989, 37:677-682.
171. Cho K.R., Rosenshein N.B., Epstein J.I. Malignant rhabdoid tumor of the kidney and soft tissues: evidence for a diverse morphological and immunocytochemical phenotype. Arch Pathol Lab Med 1989, 113:115-120.
172. Tsokos M., Kouraklis G., Chandra R.S., et al. Malignant rhabdoid tumor of the kidney and soft tissues: Evidence for a diverse morphological and immunocytochemical phenotype. Arch Pathol Lab Med 1989, 113:115-120.
173. Molenaar W.M., DeJong B., Dam-Meiring A., et al. Epithelioid sarcoma or malignant rhabdoid tumor of soft tissue. Epithelioid immunophenotype and rhabdoid karyotype. Hum Pathol 1989, 20:347-351.
174. Cavazza A., Colby T.V., Tsokos M., et al. Lung tumors with a rhabdoid phenotype. Am J Clin Pathol 1996, 105:182-188.
175. Miyagi J., Tsuhako K., Kinjo T., et al. Rhabdoid tumor of the lung is a dedifferentiated phenotype of pulmonary adenocarcinoma. Histopathology 2000, 37:37-44.
176. Bahadori H., Liebow A.A. Plasma cell granuloma of the lung. Cancer 1973, 31:191-208.
177. Lane J.D., Krohn S., Kolozzi W., et al. Plasma cell granuloma of the lung. Dis Chest 1955, 27:216-221.
178. Berardi R.S., Lee S.S., Chen H.P., et al. Inflammatory pseudotumors of the lung. Surg Gynecol Obstet 1983, 156:89-96.
179. Tang T.T., Segura A.D., Oechler H.W., et al. Inflammatory myofibrohistiocytic proliferation simulating sarcoma in children. Cancer 1990, 65:1626-1634.
180. Tan-Liu N.S., Matsubara M.D., Grillo H.C., et al. Invasive fibrous tumor of the tracheobronchial tree: Clinical and pathological study of seven cases. Hum Pathol 1989, 20:180-184.
181. Ledet S.C., Brown R.W., Cagle P.T. p53 immunostaining of the differentiation of inflammatory pseudotumor from sarcoma involving the lung. Mod Pathol 1995, 8:282-286.
182. Snyder C.S., Dell-Aquila M., Haghighi P., et al. Clonal changes in inflammatory pseudotumor of the lung. Cancer 1995, 76:1545-1549.
183. Yousem S.A., Shaw H., Cieply K. Involvement of 2p23 pulmonary inflammatory pseudotumors. Hum Pathol 2001, 32:428-433.
184. Freeman A., Geddes N., Munson P., et al. Anaplastic lymphoma kinase (ALK 1) staining and molecular analysis in inflammatory myofibroblastic tumors of the bladder: A preliminary clinicopathologic study of nine cases and review of the literature. Mod Pathol 2004, 17:765-771.
185. Lae M.E., Roche P.C., Jin L., et al. Desmoplastic small round cell tumor: A clinicopathologic, immunohistochemical and molecular study of 32 tumors. Am J Surg Pathol 2002, 26:823-835.
186. Syed S., Hague A.K., Hawkins H.K., et al. Desmoplastic small round cell tumor of the lung. Arch Pathol Lab Med 2002, 126:1226-1228.
187. Ostoros G., Orosz Z., Kovacs G., et al. Desmoplastic small round cell tumor of the pleura: A case report with unusual follow-up. Lung Cancer 2002, 36:333-336.
188. Tsuji N., Tateishi R., Ishigoro S., et al. Adenomyoepithelioma of the lung. Am J Surg Pathol 1995, 19:956-962.
189. Veeramechaneni R., Gulic J., Halldorsson A.O., et al. Benign myoepithelioma of the lung: A case report and review of the literature. Arch Pathol Lab Med 2001, 125:1494-1496.
190. Pelosi G., Fraggetta F., Maffini F., et al. Pulmonary epithelial-myoepithelial tumor of unproven malignant potential: Report of a case and review of the literature. Mod Pathol 2001, 14:521-526.
191. Ro K., Srivastava A., Tischer A.S. Bronchial epithelial-myoepithelial carcinoma. Arch Pathol Lab Med 2004, 128:92-94.
192. Dearers M., Guinee D., Koss M.N., et al. Granular cell tumors of the lung: Clinicopathologic study of 20 cases. Am J Surg Pathol 1995, 19:627-635.
193. de Araujo V.C., de Sousa S.O.M., Carvalho Y.R., et al. Application of immunohistochemistry to the diagnosis of salivary gland tumors. Appl Immunohist Mol Morphol 2000, 8:195-202.
194. Moran C.A., Suster S., Fishback N.F., et al. Primary intrapulmonary thymoma: A clinicopathologic and immunohistochemical study of eight cases. Am J Surg Pathol 1995, 19:304-312.
195. Ionescu D.N., Sasatomi E., Aldeeb D., et al. Pulmonary meningothelial-like nodules: A genotypic comparison with meningiomas. Am J Surg Pathol 2004, 28:207-214.
196. Mukhopadhyay S., El-Zammar O.A., Katzenstein A- L.A. Pulmonary meningothelial-like nodules: New insights into a common but poorly understood entity. Mod Pathol 2008, 21:348A.
197. Hochholzer L., Moran C.A., Koss M.N. Pulmonary lipomatosis: A variant of placental transmogrification. Mod Pathol 1997, 10:846-849.
198. Fidler M.E., Koomen M., Sebek B., et al. Placental transmogrification of the lung, a histologic variant of giant bullous emphysema. Am J Surg Pathol 1995, 19:563-570.
199. Brambilla E. Basaloid carcinoma of the lung. Pathology of Lung Tumors 1997, 71-82. Churchill Livingstone, New York. B. Corrin (Ed.).
200. Kargi A., Gurel D., Tuna B. The diagnostic value of TTF-1, CK5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 2007, 15:415-420.
201. Bejarano P.A., Mousavi F. Incidence and significance of cytoplasmic thyroid transcription factor-1 immunoreactivity. Arch Pathol Lab Med 2003, 127:193-195.
202. Kaimaktchiev V., Terracciano L., Tornillo L., et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal carcinomas. Mod Pathol 2004, 17:1392-1399.
203. Rossi G., Murer B., Cavazza A., et al. Primary mucinous (so-called colloid) carcinomas of the lung: A clinicopathologic and immunohistochemical study with special reference to CDX2 homeobox gene and MUC2 expression. Am J Surg Pathol 2004, 28:442-452.
204. Mazziotta R.M., Borczuk A.C., Powell C.A., et al. CDX2 immunostaining as a gastrointestinal marker: Expression in lung carcinomas is a potential pitfall. Appl Immunohistochem Mol Morphol 2005, 13:55-60.
205. Striebel J.M., Dacic S., Yousem S.A. Gross Cystic Disease Fluid Protein (GCDFP-15): expression in primary lung adenocarcinoma. Am J Surg Pathol 2008, 32:426-432.
206. Herrera G.A., Turbat-Herrera E.A., Lott R.L. S100 protein expression by primary and metastatic adenocarcinoma. Am J Clin Pathol 1988, 89:168-176.
207. Hammar S.P., Bockus D., Remington F., et al. Langerhans cells and serum precipitating antibodies against fungal antigens in bronchioloalveolar cell carcinomas: Possible association with eosinophilic granuloma. Ultrastruct Pathol 1980, 1:19-37.
208. Colasante A., Castrilli G., Aiello F.B., et al. Role of cytokines in the distribution of dendritic cells/Langerhans cell lineage in human primary carcinomas of the lung. Hum Pathol 1995, 26:866-872.
209. Hammar S.P., Bockus D., Remington F., et al. The widespread distribution of Langerhans cells in pathologic tissues: An ultrastructural and immunohistochemical study. Hum Pathol 1986, 17:894-905.
210. Dorion P., Shi J., Zhang K., et al. Utility of S100 protein in differentiating adenocarcinoma of the lung from papillary carcinoma and follicular carcinoma of the thyroid. Modern Pathol 2008, 21:340.
211. Torikata C., Ishiwata K. Intranuclear tubular structures observed in the cells of alveolar cell carcinomas of the lung. Cancer 1977, 40:1194-1201.
212. Singh G., Katyal S.L., Torikata C. Carcinoma of type II pneumocytes: Immunodiagnosis of a subtype of bronchioloalveolar carcinoma. Am J Pathol 1981, 102:195-208.
213. Singh G., Katyal S.L., Torikata C. Carcinoma of type II pneumocytes: PAS staining as a screening test for nuclear inclusions of surfactant-specific apoprotein. Cancer 1982, 50:946-948.
214. Ghadially F.N., Harawi S., Khan W. Diagnostic ultrastructural markers in alveolar cell carcinoma. J Submicrosc Cytol 1985, 17:269-278.
215. Nonaka D., Chiriboga L. Basal cell differentiation in lung adenocarcinoma. Mod Pathol 2008, 21:348A.
216. Tigrani D.Y., Weydert J.A. Expression of inhibin-alpha in primary pulmonary non-small cell carcinomas by immunohistochemistry. Mod Pathol 2008, 21:352A.
217. Zhang K., Shi J., Lin F. Expression of inhibin-alpha in non-small cell carcinoma of the lung with a focus on adenocarcinoma: A diagnostic pitfall in the evaluation of metastatic pulmonary carcinoma. Modern Pathol 2008, 21:353A.
218. Abrams H.J., Spiro R., Goldstein N. Metastases in carcinoma, analysis of 1000 autopsied cases. Cancer 1950, 3:74-85.
219. Dail D.H. Metastases to and from the lung. Pulmonary Tumors 1995, 369-403. Springer-Verlag, New York. D.H. Dail, S.P. Hammar, T.V. Colby (Eds.).
220. Wang N.P., Zee S., Zarbo R.J., et al. Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Appl Immunohist 1995, 3:99-107.
221. Ollayos C.W., Riordan P., Rushin J.M. Estrogen receptor detection in paraffin section of adenocarcinoma of colon, pancreas and lung. Arch Pathol Lab Med 1994, 118:630-632.
222. Canver C.C., Memoli V.A., Vanderveer P.L., et al. Sex hormones in non-small cell lung cancer in human beings. J Thorac Cardiovasc Surg 1994, 108:153-157.
223. Bacchi C.E., Garcia R.L., Gown A.M. Immunolocalization of estrogen and progesterone receptors in neuroendocrine tumors of lung, skin, gastrointestinal and female genital tracts. Appl Immunohist 1997, 5:17-22.
224. DiNunno L.D., Larsson L.G., Rinehart J.J., et al. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch Pathol Lab Med 2000, 124:1467-1470.
225. Dabbs D.J., Landreneau R.J., Liu Y., et al. Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. Ann Thorac Surg 2002, 73:403-406.
226. Selvaggi G., Scagliotti G.V., Torri V., et al. HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma: Impact on long-term survival. Cancer 2002, 94:2669-2674.
227. Butler A.E., Colby T.V., Weiss L., et al. Lymphoepithelioma-like carcinoma of lung. Am J Surg Pathol 1989, 13:632-639.
228. Chen F., Yan J., Lai W., et al. Epstein-Barr virus-associated nonsmall cell lung carcinoma: Undifferentiated "lymphoepithelioma-like" carcinomas as a distinct entity with better prognosis. Cancer 1998, 82:2334-2342.
229. Ginsberg S.S., Buzaid A.C., Stern H., et al. Giant cell carcinoma of the lung. Cancer 1992, 70:606-610.
230. Gustmann C., Altmannsberger M., Osborn M., et al. Cytokeratin expression and vimentin content in large cell anaplastic lymphoma and other non-Hodgkin's lymphoma. Am J Pathol 1991, 38:1413-1422.
231. Delsol G., AlSaati T., Gatter K.C., et al. Coexpression of epithelial membrane antigen (EMA), Ki-1 and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol 1988, 130:59-70.
232. Osborne B.M., Mockay B., Butler J.J., et al. Large cell lymphoma with microvillus-like projections: An ultrastructural study. Am J Clin Pathol 1983, 79:433-450.
233. Chu P.G., Arber D.A., Weiss L.M. Expression of T/NK-cell and plasma cell antigens in nonhematopoietic epithelioid neoplasms: An immunohistochemical study of 447 cases. Am J Clin Pathol 2003, 120:64-70.
234. Bishop P.W., Menasce L.P., Yates A.J., et al. An immunophenotypic survey of malignant melanomas. Histopathology 1993, 23:159-166.
235. Yoshimoto T., Higashino K., Hada T., et al. A primary lung carcinoma producing alpha-fetoprotein, carcinoembryonic antigen and human chorionic gonadotropin. Cancer 1987, 60:2744-2750.
236. Kuida C.A., Braunstein G.D., Shintaku P., et al. Human chorionic gonadotropin expression in lung, breast and renal carcinomas. Arch Pathol Lab Med 1988, 112:282-285.
237. Dirnhofer S., Freund M., Rogatsch H., et al. Selective expression of trophoblastic hormones by lung carcinoma: Neuroendocrine tumors produce human chorionic gonadotropin alpha-subunit (hCGα). Hum Pathol 2000, 31:966-972.
238. Nasu M., Soma T., Fukushima H., et al. Hepatoid carcinoma of the lung with production of alpha fetoprotein and abnormal prothrombin: An autopsy case report. Mod Pathol 1997, 10:1054-1058.
239. Cooper W.A., Thourani V.H., Gal A.A., et al. The surgical spectrum of pulmonary neuroendocrine neoplasms. Chest 2001, 119:14-18.
240. Lyda M.H., Weiss L.M. Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. Hum Pathol 2000, 31:980-987.
241. Sturm N., Rossi G., Lantuejoul S., et al. Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 2002, 33:175-182.
242. Barbareschi M., Roldo C., Zamboni G., et al. CDX-2 homeobox gene product expression in neuroendocrine tumors: Its role as a marker of intestinal neuroendocrine tumors. Am J Surg Pathol 2004, 28:1169-1176.
243. Lin X., Saad R.S., Luckasevic T.M., et al. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin. Appl Immunohistochem Mol Morphol 2007, 15:407-414.
244. Lin O., Olgac S., Green I., et al. Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish low-grade from high-grade neuroendocrine neoplasms. Am J Clin Pathol 2003, 120:209-216.
245. Pelosi G., Rodriguez J., Viale G., et al. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small cell carcinoma on biopsy specimens: A major pitfall in the management of lung cancer patients. Am J Surg Pathol 2005, 29:179-187.
246. Visscher D.W., Zarbo R.J., Trojanowski J.Q., et al. Neuroendocrine differentiation in poorly-differentiated lung carcinomas: A light microscopic and immunohistochemical study. Mod Pathol 1990, 3:508-512.
247. Linnoila R.I., Mulshine J.L., Steinberg S.M., et al. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas. Am J Clin Pathol 1988, 90:641-652.
248. Mooi W.J., Dewar A., Springall D., et al. Non-small cell lung carcinomas with neuroendocrine features: A light microscopic, immunohistochemical and ultrastructural study of 11 cases. Histopathology 1988, 13:329-337.
249. Wick M.R., Berg L.C., Hertz M.I. Large cell carcinoma of the lung with neuroendocrine differentiation: A comparison with large cell "undifferentiated" pulmonary tumors. Am J Clin Pathol 1992, 97:796-805.
250. Loy T.S., Darkow G.V.D., Quesenberry J.T. Immunostaining in the diagnosis of pulmonary neuroendocrine carcinomas: An immunohistochemical study with ultrastructural correlations. Am J Surg Pathol 1995, 19:173-182.
251. Xu H., Bourne P.A., Spaulding B.O., et al. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol 2007, 38:555-563.
252. Schleusener J.T., Tazelaar H.D., Jung S., et al. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated non-small cell lung carcinoma. Cancer 1996, 77:1284-1291.
253. Ralston J., Chiriboga L., Nonaka D. MASH1: A useful marker in differentiating pulmonary small cell carcinoma from Merkel cell carcinoma. Mod Pathol 2008, 21:1357-1362.
254. Zhu C.Q., Shih W., Ling C.H., et al. Immunohistochemical markers of prognosis in non-small cell lung cancer: A review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006, 59:790-800.
255. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.[see comment]. N Engl J Med 2006, 355:983-991.
256. Simon G., Sharma A., Li X., et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007, 25:2741-2746.
257. Clark G.M., Zborowski D.M., Culbertson J.L., et al. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J Thorac Oncol 2006, 1:837-846.
258. Jeon Y.K., Sung S.-W., Chung J.-H., et al. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 2006, 54:387-398.
259. Tsao M-S, Sakurada A, Cutz J-C, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. [see comment][erratum appears in N Engl J Med. 2006:355(16):1746]. N Engl J Med. 2005;353:133-144.
260. Hirsch F.R., Dziadziuszko R., Thatcher N., et al. Epidermal growth factor receptor immunohistochemistry: Comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. Cancer 2008, 112:1114-1121.
261. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.[see comment]. N Engl J Med 2004, 350:2129-2139.
262. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy.[see comment]. Science 2004, 304:1497-1500.
263. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101:13306-13311.
264. Jackman D.M., Yeap B.Y., Sequist L.V., et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12:3908-3914.
265. Pao W., Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: Searching for the ideal method. [comment]. Clin Cancer Res 2007, 13:4954-4955.
266. Sequist L.V., Joshi V.A., Janne P.A., et al. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res 2006, 12:4403s-4408s.
267. Shih J.Y., Gow C.H., Yu C.J., et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. [see comment]. Int J Cancer 2006, 118:963-969.
268. Shih J.Y., Gow C.H., Yang P.C. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. N Engl J Med 2005, 353:207-208.
269. Bean J., Brennan C., Shih J.Y., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007, 104:20932-20937.
270. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
271. Ahrendt S.A., Decker P.A., Alawi E.A., et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001, 92:1525-1530.
272. Eberhard D.A., Johnson B.E., Amler L.C., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.[see comment]. J Clin Oncol 2005, 23:5900-5909.
273. Shigematsu H., Gazdar A.F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006, 118:257-262.
274. Cappuzzo F., Hirsch F.R., Rossi E., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.[see comment][comment]. J Natl Cancer Inst 2005, 97:643-655.
275. Daniele L., Macri L., Schena M., et al. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. Mol Cancer Ther 2007, 6:1223-1229.
276. Gallegos Ruiz M.I., Floor K., Vos W., et al. Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer; a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization. Histopathology 2007, 51:631-637.
277. Hirsch F.R., Varella-Garcia M., McCoy J., et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study. [see comment]. J Clin Oncol 2005, 23:6838-6845.
278. Johnson B.E., Janne P.A. Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?[see comment][comment]. J Clin Oncol 2005, 23:6813-6816.
279. Hirsch F.R., Herbst R.S., Olsen C., et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008, 26:3351-3357.
280. Sholl L.M., John Iafrate A., Chou Y.P., et al. Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. Mod Pathol 2007, 20:1028-1035.
281. Barletta J.A., Weir B.A., Perner S., Johnson L., Rubin M.A., et al. Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinomas. Mod Pathol 2008, 21:335A.
282. Beasley M.B., Castro C.Y., Garza L., et al. Expression of HIF-1 alpha in pulmonary non-small cell carcinomas and neuroendocrine carcinomas-a tissue microarray analysis of 442 cases. Mod Pathol 2008, 21:336A.
283. Beheshti J., Sabo E., Janne P.A., et al. TTF-1 positivity is a sensitive predictor of EGFR mutation and treatment response in pulmonary adenocarcinomas, by pathologist interpretation and by image analysis. Mod Pathol 2008, 21:336A.
284. Kundu U.R., Li W., Tan D., et al. Alpha-methylacyl-co-a-racemase (AMACR) expression is a biomarker of poor prognosis in stage 1 and 2 large cell carcinomas of the lung. Mod Pathol 2008, 21:345A.
285. Perner S., Demichelis F., Johnson L., et al. TTF1 amplification defines TTF1 overexpression in lung adenocarcinomas. Mod Pathol 2008, 21:349A.
286. Vohra P., Cagle P.T., Allen T.C., et al. Tissue microarray study of RNA-binding protein IMP3 in primary non-small cell lung cancers: Prediction of survival in early stage squamous cell carcinomas. Mod Pathol 2008, 21:352A.
287. Cutz J.-C., Tsakaridis T.S., Wright J., et al. Immunohistochemistry for phosphorylated EGF receptor predicts survival and phosphorylated ERK predicts tumor response to chemo-radiotherapy in unresectable, locally advanced non-small cell lung cancer patients. Mod Pathol 2008, 21:339A.
288. Li Q.K., Tully E., Askin F.B., et al. Overexpression of NRF2 is correlated with elevated p53 levels in pulmonary papillary adenocarcinoma by tissue microarray analysis. Mod Pathol 2008, 21:345A.
289. Luu M., Sabo E., Resnick M., et al. Prognostic value of aspartyl (asparaginyl) hydroxylase (AAH) in lung carcinomas: Correlation with survival. Mod Pathol 2008, 21:346A.
290. Shahjahan M., Zhai Q.J., Allen T.C., et al. ProEx C expression in non-small cell lung cancers (NSCLC) is associated with longer patient survival. Mod Pathol 2008, 21:350A.
291. Sienko A.E., Allen T.C., Barrios R., et al. Expression of galectin-4 in non-small cell lung carcinoma (NSCLC) and correlation with survival. Mod Pathol 2008, 21:351A.
292. Song J., Tretiakova M.S., Salgia R., et al. c-Met expression in pulmonary neuroendocrine tumors. Mod Pathol 2008, 21:351A-352A.
293. Haque A.K., Singhal N., Allen T., et al. Lack of E-cadherin and Pan-cadherin immunoexpression is associated with metastasis in small cell lung cancer. Mod Pathol 2008, 21:342A.
294. Homan S.M., Sheehan C.E., Ross J.S., et al. Downregulation of GADD45a protein expression is associated with advanced tumor stage and decreased survival in squamous cell carcinoma of the lung. Mod Pathol 2008, 21:343A.
295. Malik A., Krishnaswamy S., Gong C., et al. RON overexpression and activation in primary and metastatic lung carcinoma. Mod Pathol 2008, 21:346A.
296. Lonardo F., Pass H.I., Lucas D.R. Immunohistochemistry frequently detects c-Kit expression in pulmonary small cell carcinoma and may help select clinical subsets for a novel form of chemotherapy. Appl Immunohist Mol Morphol 2003, 11:51-55.
297. Pelosi G., Barisella M., Pasini F., et al. CD117 immunoreactivity in stage I adenocarcinoma and squamous carcinoma of the lung: Relevance to prognosis in a subset of adenocarcinoma patients. Mod Pathol 2004, 17:711-721.
298. Casali C., Stefani A., Rossi G., et al. The prognostic role of c-Kit protein expression in resected large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg 2004, 77:252-253.
299. Butnor K.J., Burchette J.L., Sporn T.A., et al. The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: A study of 96 cases using a single-source antibody with a review of the literature. Arch Pathol Lab Med 2004, 128:538-543.
300. Maddau C., Confortini M., Bisanzi S., et al. Prognostic significance of p53 and Ki-67 antigen expression in surgically treated non-small cell lung cancer: Immunocytochemical detection with imprint cytology. Am J Clin Pathol 2006, 125:425-431.
301. Kobayashi S., Kubo H., Suzuki T., et al. Endogenous secretory receptor for advanced glycation end products in non-small cell lung carcinoma. Am J Respir Crit Care Med 2007, 175:184-189.
302. Allen T.C., Granville L.A., Cagle P.T., et al. Expression of glutathione S-transferase p and glutathione synthase correlates with survival in early stage non-small cell carcinomas of the lung. Hum Pathol 2007, 38:220-227.
303. Lee Y.-C., Wu C.-T., Kuo S.-W., et al. Significance of extranodal extension of regional lymph nodes in surgically resected non-small cell lung cancer. Chest 2007, 131:993-999.
304. Fukuoka J., Dracheva T., Shih J.H., et al. Desmoglein 3 as a prognostic factor in lung cancer. Hum Pathol 2007, 38:276-283.
305. Aviel-Ronen S., Lau S.K., Pintilie M., et al. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol 2008, 21:817-825.
306. LaPoint R.J.A., Bourne P.A., Wang H.L., et al. Coexpression of c-kit and bcl-2 in small cell carcinoma and large cell neuroendocrine carcinoma of the lung. Appl Immunohistochem Mol Morphol 2007, 15:401-406.
307. Meyronet D., Massoma P., Thivolet F., et al. Extensive expression of collapsing response mediator protein 5 (CRMP5) is a specific marker of high-grade neuroendocrine carcinoma. Am J Surg Pathol 2008, 32:1699-1708.
308. Yousem S.A., Nikiforova M., Nikiforov Y. The histopathology of BRAF-V600E-mutated lung adenocarcinoma. Am J Surg Pathol 2008, 32:1317-1321.
309. Hammar S.P. Pleural diseases. Pulmonary Pathology Tumors 1995, 405-530. Springer-Verlag, New York. D.H. Dail, S.P. Hammar, T.V. Colby (Eds.).
310. Davies J. Human Developmental Anatomy 1963, Roland Press, New York, 51-52.
311. Bolen J.W., Hammar S.P., McNutt M.A. Reactive and neoplastic serosal tissue: A light-microscopic, ultrastructural and immunocytochemical study. Am J Surg Pathol 1986, 10:34-47.
312. Selikoff I.J., Seidman H. Asbestos-associated deaths among insulation workers in the United States and Canada, 1967-1987. Ann NY Acad Sci 1991, 643:1-14.
313. Battifora H., McCaughey W.T.E. Tumors of the serosal membranes 1995, Armed Forces Institute of Pathology, Washington DC, 17-88.
314. Butnor K.J., Sporn T.A., Hammar S.P., et al. Well-differentiated papillary mesothelioma. Am J Surg Pathol 2001, 25:1304-1309.
315. Galateau-Salle F., Vignaud J., Burke L., et al. Well-differentiated papillary mesothelioma of the pleura: A series of 24 cases. Am J Surg Pathol 2004, 28:534-540.
316. Henderson D.W., Shilkin K.B., Whitaker D. Reactive mesothelial hyperplasia vs. mesothelioma, including mesothelioma in situ: A brief review. Am J Clin Pathol 1998, 110:397-404.
317. US-Canadian Mesothelioma Reference Panel, Churg A., Colby T.V., Cagle P., Corson J., Gibbs A.R., Gilks B., Grimes M., Hammar S., Roggli V., Travis W.D. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000, 24:1183-1200.
318. Henderson D.W., Comin C.E., Hammar S.P., et al. Malignant mesothelioma of the pleura: Current surgical pathology. Pathology of Lung Tumors 1997, 241-280. Churchill Livingstone, New York. B. Corrin (Ed.).
319. Ordonez N.G. The immunohistochemical diagnosis of epithelial mesothelioma. Hum Pathol 1999, 30:313-323.
320. Blobel G.A., Moll R., Franke W.W., et al. The intermediate filament cytoskeleton of malignant mesothelioma and its diagnostic significance. Am J Pathol 1985, 121:235-247.
321. Blobel G.A., Moll R., Franke W.W., et al. Cytokeratins in normal lung and lung carcinomas. I. Adenocarcinomas, squamous cell carcinomas and cultured cell lines. Virchows Arch Cell Pathol 1984, 45:407-429.
322. Moll R., Dhovailly D., Sun T.T. Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas: An immunohistochemical study using monoclonal antibody AE14. Virchows Archiv B Cell Pathol 1989, 58:129-145.
323. Clover J., Oates J., Edwards C. Anti-cytokeratin 5/6: A positive marker for epithelial mesothelioma. Histopathology 1997, 31:140-143.
324. Kahn H.J., Thorner P.S., Yeager H., et al. Immunohistochemical localization of pre-keratin filaments in benign and malignant cells in effusions: Comparison with intermediate filament distribution by electron microscopy. Am J Pathol 1982, 109:206-214.
325. Kahn H.J., Thorner P.S., Yeger H., et al. Distinct keratin patterns demonstrated by immunoperoxidase staining of adenocarcinomas, carcinoids and mesotheliomas using polyclonal and monoclonal keratin antibodies. Am J Clin Pathol 1986, 86:566-574.
326. Montag A.G., Pinkus G.S., Corson J.M. Keratin protein reactivity immunoreactivity of sarcomatoid and mixed types of diffuse malignant mesotheliomas: An immunoperoxidase study of 30 cases. Hum Pathol 1988, 19:336-342.
327. Battifora H. The pleura. Diagnostic Surgical Pathology 1989, Volume I:829-855. Raven Press, New York. S.S. Sternberg (Ed.).
328. Roggli V.L., Kolbeck J., Sanfilippo F., et al. Pathology of human mesothelioma: Etiologic and diagnostic considerations. Pathol Annu 1987, 22(pt 2):91-131.
329. Al-Izzi M., Thurlow N.P., Corrin B. Pleural mesothelioma of connective tissue type, localized fibrous tumour of the pleura and reactive submesothelial hyperplasia: An immunohistochemical comparison. J Pathol 1989, 157:41-44.
330. Mayall F.G., Goddard H., Gibbs A.R. Intermediate filament expression in mesotheliomas: leiomyoid mesotheliomas are not uncommon. Histopathol 1992, 21:453-457.
331. Yousem S.A., Hochholzer L. Malignant mesotheliomas with osseous and cartilaginous differentiation. Arch Pathol Lab Invest 1987, 111:62-66.
332. Wirth P.R., Legler J., Wright G.L. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma. Cancer 1991, 67:655-662.
333. Carter D., Otis C.N. Three types of spindle cell tumors of pleura: Fibroma, sarcoma and sarcomatoid mesothelioma. Am J Surg Pathol 1988, 12:747-753.
334. Azumi N., Battifora H., Carlson G., et al. Sarcomatous (spindle-cell) mesothelioma of pleura: Immunohistochemical study. Lab Invest 1989, 60:4A.
335. Lucas D.R., Pass H.I., Madan S.K., et al. Sarcomatoid mesothelioma and its histological mimics: A comparative immunohistochemical study. Histopathology 2003, 42:270-279.
336. Attanoos R.L., Dojcinov S.D., Webb R., Gibbs A.R. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathology 2000, 37:224-231.
337. McNutt M.A., Bolen J.W., Gown A.M., et al. Coexpression of intermediate filaments in human epithelial neoplasms. Ultrastruct Pathol 1985, 9:31-43.
338. Azumi N., Battifora H. The distribution of vimentin and keratin in epithelial and non-epithelial neoplasms. A comprehensive study on formalin and alcohol-fixed tumors. Am J Clin Pathol 1987, 88:286-296.
339. Raymond W.A., Leong A.S.Y. Vimentin-a new prognostic marker in breast carcinoma. J Pathol 1989, 158:107-114.
340. Churg A. Immunohistochemical staining for vimentin and keratin in malignant mesothelioma. Am J Surg Pathol 1985, 9:360-365.
341. Jasani B., Edwards R.E., Thomas N.D., et al. The use of vimentin antibodies in the diagnosis of malignant mesothelioma. Virch Arch A Pathol Anat 1985, 406:441-448.
342. Mullink H., Henzen-Logmans S.C., Alons-van Kordelaan J.J.M., et al. Simultaneous immunoenzyme staining of vimentin and cytokeratins with monoclonal antibodies as an aid in the differential diagnosis of malignant mesothelioma from pulmonary adenocarcinoma. Virch Arch B Pathol Anat 1986, 42:55-65.
343. Andersen C., Blumcke I., Celio M.R. Calcium-binding proteins: Selective markers of nerve cells. Cell Tissue Res 1993, 271:181-208.
344. Schwaller B., Buchwald P., Blucke I., et al. Characterization of a polyclonal antiserum against the purified human recombinant calcium binding protein calretinin. Cell Calcium 1993, 14:639-648.
345. Gotzos V., Schwaller B., Hertzel N., et al. Expression of the calcium binding protein calretinin in Wi Dr cells and its correlation to their cell cycle. Exp Cell Res 1992, 202:292-302.
346. Doglioni C., Dei Tos A.P., Laurino L., et al. Calretinin: A novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996, 20:1037-1046.
347. Barberis M.C.P., Faleri M., Veronese S., et al. Calretinin: A selective marker of normal and neoplastic mesothelial cells in serous effusions. Acta Cytol 1997, 41:1757-1761.
348. Leers M.P.G., Aarts M.M.J., Theunissen P.H.M.H. E-cadherin and calretinin: A useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathol 1998, 32:209-216.
349. Ordonez N.G. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 1998, 10:929-933.
350. Chenard-Neu M.P., Kabou A., Mechine A., et al. Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma: evaluation of 5 new and 6 traditional antibodies. Ann Pathol 1998, 18:460-465.
351. Cury P.M., Butcher D.N., Fisher C., et al. Value of mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin and CD44H in distinguishing epithelioid mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol 2000, 13:107-112.
352. Oates J., Edwards C. HBME-1, MOC-31, WT1 and calretinin: An assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathol 2000, 36:341-347.
353. Chieng D.C., Yee H., Schaefer D., et al. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions. Cancer 2000, 25:194-200.
354. O'Hara C.J., Corson J.M., Pinkus G.S., et al. ME1: A monoclonal antibody that distinguishes epithelial-type mesothelioma from pulmonary adenocarcinoma and extra-pulmonary malignancies. Am J Pathol 1990, 136:421-428.
355. Sheibani K., Esteban J.M., Bailey A., et al. Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum Pathol 1992, 23:107-116.
356. Hammar S.P., Bolen J.W., Bockus D., et al. Ultrastructural and immunohistochemical features of common lung tumors: An overview. Ultrastruct Pathol 1985, 9:283-318.
357. Walz R., Koch H.K. Malignant pleural mesotheliomas: Some aspects of epidemiology, differential diagnosis and prognosis. Histological and immunohistochemical evaluation and follow-up of mesotheliomas diagnosed from 1964 to January 1985. Pathol Res Pract 1990, 186:124-134.
358. Wick M.R., Loy T., Mills S.E., et al. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: A histochemical, ultrastructural and immunohistologic study of 103 cases. Hum Pathol 1990, 21:759-766.
359. Henderson D.W., Shilkin K.B., Whitaker D., et al. The pathology of mesothelioma, including immunohistology and ultrastructure. Malignant Mesothelioma 1992, 69-139. Hemisphere, New York. D.W. Henderson, K.B. Shilkin, S.L. Langlois, D. Whitaker (Eds.).
360. Fink L., Collins C.L., Schaefer R., et al. Thrombomodulin expression can be used to differentiate between mesotheliomas and adenocarcinomas. Lab Invest 1992, 66:113A.
361. Collins C.L., Ordonez N.G., Schaefer R., et al. Thrombomodulin expression and pulmonary adenocarcinoma. Am J Pathol 1992, 141:827-833.
362. Brown R.W., Clark G.M., Tandon A.K., et al. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol 1993, 24:347-354.
363. Ascoli V., Scalzo C.C., Taccogna S., et al. The diagnostic value of thrombomodulin immunolocalization in serous effusions. Arch Pathol Lab Med 1995, 119:1136-1140.
364. Geiger B., Ayalon O. Cadherins. Annu Rev Cell Biol 1992, 8:307-332.
365. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991, 251:1451-1455.
366. Hatta K., Takagi S., Fujisawa H., et al. Spatial and temporal expression pattern of N-cadherin cell adhesion molecules correlated with morphogenetic processes of chicken embryos. Dev Biol 1987, 120:215-227.
367. Peralta-Soler A., Knudsen K.A., Jaurand M.C., et al. The differential expression of N-cadherin, E-cadherin distinguished pleural mesotheliomas from lung adenocarcinomas. Hum Pathol 1995, 26:1363-1369.
368. Han A.C., Peralta-Soler A., Knudsen K.A., et al. Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues. Hum Pathol 1997, 28:641-645.
369. Ordonez N.G. Value of E-cadherin and N-cadherin immunostaining in the diagnosis of mesothelioma. Hum Pathol 2003, 34:749-755.
370. Amin K.M., Litzky L.A., Smythe W.R., et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995, 146:344-356.
371. Kumar-Singh S., Segers K., Rodeck O., et al. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 growth factor expression, cell-type transition and prognosis. J Pathol 1997, 181:67-74.
372. Walker C., Rutlen F., Yuan X., et al. Wilms' tumor suppressor gene expression in rat and human mesothelioma. Cancer Res 1994, 54:1301-1306.
373. Ordonez N.G. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003, 27:1418-1428.
374. Chu A.Y., Litzky L.A., Pasha T.L., et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod
375. Comin C.E., Dini S., Novelli L., et al. h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type. Am J Surg Pathol 2006, 30:463-469.
376. Shivley J.E., Beatty J.D. CEA-related antigens: Molecular biology and clinical significance. CRC Crit Rev Oncol Hematol 1985, 2:355-399.
377. Thompson J., Grunert F., Zimmermann W. Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives. J Clin Labor Anal 1991, 5:344-366.
378. Hammarstrom S., Khan W.N., Teglund S., et al. The carcinoembryonic antigen family. Structure of Antigens 1993, 341-376. CRC Press, Boca Raton. M.H.V. Van Regenmortel (Ed.).
379. Hammarstrom S., Olsen A., Teglund S., et al. The nature and expression of the human CEA family. Cell Adhesion and Clinical Perspectives 1997, 1-30. Harwood Academic Publishers, Amsterdam. C. Stanners (Ed.).
380. Hammarstrom S. The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues. Cancer Biol 1999, 9:67-81.
381. Wang N.-S., Huang S.-N., Gold P. Absence of carcinoembryonic antigen-like material in mesothelioma: An immunohistochemical differentiation from other lung cancers. Cancer 1979, 44:437-943.
382. Whitaker D., Shilkin K.B. Carcinoembryonic antigen in the tissue diagnosis of malignant mesothelioma. Lancet 1981, 1:1369-1370.
383. Whitaker D., Sterret G.F., Shilkin K.B. Detection of tissue CEA-like substance as an aid in the differential diagnosis of malignant mesothelioma. Pathology 1982, 14:255-258.
384. Sheibani K., Battifora H. Leu-M1 positivity is not specific for Hodgkin's disease. Am J Clin Pathol 1985, 84:682.
385. Sheibani K., Battifora H., Burke J.S., et al. Leu-M1 in human neoplasms: An immunohistologic study of 400 cases. Am J Surg Pathol 1986, 10:227-236.
386. Sheibani K., Battifora H., Burke J. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas: An immunohistologic analysis demonstrating the value of Leu-M1 antigen. Am J Pathol 1986, 123:212-219.
387. Sheibani K., Azumi N., Battifora H. Further evidence demonstrating the value of LeuM1 antigen in differential diagnosis of malignant mesothelioma and adenocarcinoma: An immunohistologic evaluation of 395 cases. Lab Invest 1988, 58:84A.
388. Otis C.N., Carter O., Cole S., et al. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. Am J Surg Pathol 1987, 11:445-456.
389. Szpak C.A., Johnston W.W., Roggli V., et al. The diagnostic distinction between malignant mesothelioma and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am J Pathol 1986, 122:252-260.
390. Ordonez N.G. The immunohistochemical diagnosis of mesothelioma: Differentiation of mesothelioma and lung adenocarcinoma. Am J Surg Pathol 1989, 13:276-291.
391. Bollinger D.J., Wick M.R., Dehner L.P., et al. Peritoneal malignant mesothelioma versus serous papillary adenocarcinoma: A histochemical and immunohistochemical comparison. Am J Surg Pathol 1989, 13:659-670.
392. Latza V., Niedobitek G., Schwarting R., et al. Ber-EP4: New monoclonal antibody which distinguishes epithelia from mesothelia. J Clin Pathol 1990, 43:213-219.
393. Sheibani K., Shin S.S., Kezirian J., et al. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. Am J Surg Pathol 1991, 15:779-784.
394. Gaffey M.J., Mills S.E., Swanson P.E., et al. Immunoreactivity for Ber-EP4 in adenocarcinomas, adenomatoid tumors and malignant mesotheliomas. Am J Surg Pathol 1992, 16:593-599.
395. Souhami R.L., Beverly P.C.L., Bobrow L.G. Antigens of small cell lung cancer. First International Workshop. Lancet 1987, 2:325-326.
396. Riutenbeek T., Gouw A.S.H., Poppema S. Immunocytology of body cavity fluids: MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells. Arch Pathol Lab Med 1994, 118:265-269.
397. DeLeij L., Broers J., Ramaekers F., et al. Monoclonal antibodies in clinical and experimental pathology of lung cancer. Applications of Monoclonal Antibodies in Tumor Pathology 1987, 191-210. Martinus Nijhoff, Dordrecht. D.J. Roiter, G.J. Fleuren, S.O. Warner (Eds.).
398. Delahaye M., Hoogsteden H.C., van der Kwast T.H. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. J Pathol 1991, 165:137-143.
399. Ordonez N.G. Value of MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Hum Pathol 1998, 29:166-169.
400. Jordon D., Jagirdar J., Kaneko M. Blood group antigens Lewis x and Lewis y in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. Am J Pathol 1989, 135:931-937.
401. Riera J.R., Astengo-Osuna C., Longmate J.A., et al. The immunohistochemical diagnostic panel for epithelial mesothelioma. A reevaluation after heat-induced epitope retrieval. Am J Surg Pathol 1997, 21:1409-1419.
402. Kinsella A.R., Green B., Lepts G.C., et al. The role of cell-cell adhesion molecule E-cadherin in large bowel tumour cell invasion and metastasis. Br J Cancer 1993, 67:904-909.
403. Williams C.L., Hayes V.Y., Hummel A.M., et al. Regulation of E-cadherin mediated adhesion by muscarinic acetylcholine receptor in small cell lung carcinoma. J Cell Biol 1993, 121:643-654.
404. Kawai T., Suzuki M., Torikata C., et al. Expression of blood group-related antigens and Helix pomatia agglutinin in malignant pleural mesothelioma and pulmonary adenocarcinoma. Hum Pathol 1991, 22:118-124.
405. Mayall F.G., Goddard H., Gibbs A.R. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J Pathol 1992, 168:377-381.
406. Ramael M., Lemmens G., Eerdekens C., et al. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 1992, 168:371-375.
407. Mayall F.G., Goddard H., Gibbs A.R. The frequency of p53 immunostaining in asbestos-associated mesotheliomas. Histopathology 1993, 22:383-386.
408. Hurlimann J. Desmin and neural marker expression in mesothelial cells and mesotheliomas. Hum Pathol 1994, 25:753-757.
409. Azumi N., Underhill C.B., Kagan E., et al. A novel biotinylated probe specific for hyaluronate. Am J Surg Pathol 1992, 16:116-121.
410. Thylen A., Wallin J., Martensson G. Hyaluronan in serum as an indicator of progressive disease in hyaluronan-producing malignant mesothelioma. Cancer 1999, 86:2000-2005.
411. Martensson G., Thylen A., Lindquist U., et al. The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods. Cancer 1994, 73:1406-1410.
412. Thylen A., Levin-Jacobsen A.M., Hjerpe A., et al. Immunohistochemical differences between hyaluronan and non-hyaluronan-producing malignant mesothelioma. Eur Respir J 1997, 10:404-408.
413. Kabawat S.E., Bast R.C., Bhan A.K., et al. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid and clear cell types. Am J Clin Pathol 1983, 79:98-104.
414. Kabawat S.E., Bast R.C., Bhan A.K., et al. Tissue distribution of celomic epithelium related antigen recognized by monoclonal antibody OC-125. Int J Gynecol Pathol 1983, 2:275-285.
415. Dabbs D.J., Geisinger K.R. Selective application of immunohistochemistry in gynecological neoplasms. Pathol Annu 1993, 28(pt 1):329-353.
416. Bast R.C., Freeney M., Lazarus H., et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981, 68:1331-1337.
417. Koelma I.A., Nap M., Rodenburg C.J., et al. The value of tumor marker CA-125 in surgical pathology. Histopathology 1987, 11:287-294.
418. Nanbu Y., Fujii S., Konishi I., et al. Immunohistochemical localization of CA-130 in fetal tissue and in normal and neoplastic tissues of the female genital tract. Asia Oceania J Obstet Gynecol 1990, 16:379-387.
419. Tamura S., Yamaguchi K., Terada M., et al. Immunohistochemical analysis of CA19-9, SLX and CA-125 in adenoidcystic carcinoma of trachea and bronchus. Nippon Kyobu Shikkan Gakkai Zasshi 1992, 3:407-411.
420. Zhou J., Iwasa Y., Konishi I., et al. Papillary serous carcinoma of the peritoneum in women: A clinicopathologic and immunohistochemical study. Cancer 1995, 76:429-436.
421. Nouwen E.J., Pollet D.E., Eerdekens M.W., et al. Immunohistochemical localization of placental alkaline phosphatase, carcinoembryonic antigen and cancer antigen 125 in normal and neoplastic human lung. Cancer Res 1986, 46:866-876.
422. Bateman A.C., al-Talib R.K., Newman T., et al. Immunohistochemical phenotype of malignant mesothelioma: Predictive value of CA-125 and HBME-1 expression. Histopathology 1997, 30:49-56.
423. Nap M. Immunohistochemistry of CA-125: Unusual expression in normal tissues, distribution in the human fetus and questions around its application in diagnostic pathology. Int J Biol Markers 1998, 13:210-215.
424. O'Brien T.J., Raymond L.M., Bannon G.A., et al. New monoclonal antibodies identify the glycoprotein carrying the CA-125 epitope. Am J Obst Gynecol 1991, 61:1857-1864.
425. Okamoto H., Matsuno Y., Noguchi M., et al. Malignant pleural mesothelioma producing chorionic gonadotropin: Report of two cases. Am J Surg Pathol 1992, 16:969-974.
426. McAuley P., Asa S.L., Chiv B., et al. Parathyroid hormone-like peptide in normal and neoplastic mesothelial cells. Cancer 1990, 66:1975-1979.
427. Tateyama H., Eimoto T., Tada T., et al. Immunoreactivity of a new CD5 antibody with normal epithelium and malignant tumors including thymic carcinoma. Am J Clin Pathol 1999, 111:235-240.
428. Yaziji H., Battifora H., Barry T.S., et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: Identification of a three-body immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006, 19:514-523.
429. Marchevsky A.M. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med 2008, 132:397-401.
430. Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: A consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med [in press].
431. Chirieac L., Pinkus G., Pinkus J. Sarcomatoid malignant mesothelioma: Immunohistochemical characteristics of 24 cases. Mod Pathol 2006, 19:305A. Abstract 1422.
432. Ordonez N.G. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005, 36:372-380.
433. Hinterberger M., Reineke T., Storz M., et al. D2-40 and calretinin: A tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod Pathol 2007, 20:248-255.
434. Klebe S., Mahar A., Henderson D.W., et al. Malignant mesothelioma with heterologous elements: Clinicopathological correlation of 27 cases and literature review. Mod Pathol 2008, 21:1084-1094.
435. Krishna J., Haqqani M.T. Liposarcomatous differentiation in diffuse pleural mesothelioma. Thorax 1993, 48:409-410.
436. Hammar S.P., Bockus D., Remington F. Metastatic tumors of unknown origin: An ultrastructural analysis of 265 cases. Ultrastruct Pathol 1987, 11:209-250.
437. Gaber A.O., Rice P., Eaton C., et al. Metastatic malignant disease of unknown origin. Am J Surg Pathol 1983, 145:493-497.
438. Crotty T.B., Myers J.L., Katzenstein A.L., et al. Localized malignant mesothelioma: A clinicopathologic and flow cytometric study. Am J Surg Pathol 1994, 18:357-363.
439. Allen T.C., Cagle P.T., Churg A.M., et al. Localized malignant mesothelioma. Am J Surg Pathol 2005, 29:866-873.
440. Hammar S.P., Henderson D.W., Klebe S., et al. Neoplasms of the pleura. Dail and Hammar's Pulmonary Pathology 2008:558-734, Springer, New York. 3rd ed. J.F. Tomashefski (Ed.).
441. Attanoos R.L., Griffin A., Gibbs A.R., et al. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 2003, 43:231-238.
442. Wu M., Sun Y., Li G., et al. Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions. Am J Clin Pathol 2007, 128:783-787.
443. Kato Y., Tsuta K., Ski K., et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 2007, 20:215-220.
444. Acurio A., Arif Q., Gattuso P., et al. Value of immunohistochemical markers in differentiating benign from malignant mesothelial lesions. Mod Pathol 2008, 21:334A.
445. Briselli M., Mark E.J., Dickersin G.R. Solitary fibrous tumors of the pleura: Eight new cases and review of 360 cases in the literature. Cancer 1981, 47:2678-2689.
446. Doucet J., Dardick I., Srigley J.R., et al. Localized fibrous tumour of serosal surfaces. Virch Arch Pathol Anat 1986, 409:349-363.
447. England D.M., Hochholzer L., McCarthy M.J. Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases. Am J Surg Pathol 1989, 13:640-658.
448. van de Rijn M., Lombard C.M., Rouse R.V. Expression of CD34 by solitary fibrous tumors of the pleura, mediastinum and lung. Am J Surg Pathol 1994, 18:814-820.
449. Flint A., Weiss S.W. CD-34 and keratin expression distinguishes solitary fibrous tumor (fibrous mesothelioma) of pleura from desmoplastic mesothelioma. Hum Pathol 1995, 26:428-431.
450. Hasegawa T., Matsuno Y., Shimoda T., et al. Frequent expression of bcl-2 protein in solitary fibrous tumors. Jpn J Clin Oncol 1998, 28:86-91.
451. Schirosi L., Lantuejoul S., Cavazza A., et al. Pleuro-pulmonary solitary fibrous tumors: A clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR. Am J Surg Pathol 2008, 32:1627-1642.
452. de Perrot M., Fischer S., Bründler M.A., et al. Solitary fibrous tumors of the pleura. Ann Thorac Surg 2002, 74:285-293.
453. Babolini G., Blasi A. The pleural form of primary cancer of the lung. Dis of Chest 1956, 29:314-323.
454. Harwood T.R., Gracey D.R., Yokoo H. Pseudomesotheliomatous carcinoma of the lung. Am J Clin Pathol 1976, 65:159-167.
455. Koss M., Travis W., Moran C., et al. Pseudomesotheliomatous adenocarcinoma: A reappraisal. Semin Diag Pathol 1992, 9:117-123.
456. Hartman C.-A., Schutze H. Mesothelioma-like tumors of the pleura: A review of 72 cases. Cancer Res Clin Oncol 1994, 120:331-347.
457. Koss M.N., Fleming M., Przygodzki R.M., et al. Adenocarcinoma simulating mesothelioma: A clinicopathologic and immunohistochemical study of 29 cases. Ann Diagn Pathol 1998, 2:93-102.
458. Robb J.A., Hammar S.P., Yokoo H. Pseudomesotheliomatous carcinoma of lung. Lab Invest 1993, 68:134A.
459. Attanoos R.L., Gibbs A.R. "Pseudomesotheliomatous" carcinomas of the pleura: A 10-year analysis of cases from the Environmental Lung Disease Research Group. Cardiff Histopathol 2003, 43:444-452.
460. Battifora H. Epithelioid hemangioendothelioma imitating mesothelioma. Appl Immunohistochem 1993, 1:220-221.
461. Lin B.T.-Y., Colby T., Gown A.M., et al. Malignant vascular tumors of the serous membranes mimicking mesothelioma: A report of 14 cases. Am J Surg Pathol 1996, 20:1431-1439.
462. Gray M.H., Rosenberg A.E., Dickersin G.R., et al. Cytokeratin expression in epithelioid vascular neoplasms. Hum Pathol 1990, 21:212-217.
463. Pinkard N.B., Wilson R.W., Lawless N., et al. Calcifying fibrous pseudotumor of pleura: A report of three cases of a newly described entity involving the pleura. Am J Clin Pathol 1996, 105:189-194.
464. Wilson R.W., Galateau-Salle F., Moran C.A. Desmoid tumors of the pleura: A clinicopathologic mimic of localized fibrous tumor. Mod Pathol 1999, 12:9-14.
465. Andino L., Cagle P.T., Murer B., et al. Pleuropulmonary desmoids tumors: Immunohistochemical comparison with solitary fibrous tumors and assessment of β-catenin and cyclin D1 expression. Arch Pathol Lab Med 2006, 130:1503-1509.
466. Moran C.A., Travis W.D., Rosada-de-Christenson M., et al. Thymomas presenting as pleural tumors: Report of eight cases. Am J Surg Pathol 1992, 16:138-144.
467. Payne C.B., Morningstar W.A., Chester E.H. Thymoma of the pleura masquerading as diffuse mesothelioma. Am Rev Respir Dis 1966, 94:441-446.
468. Honma K., Shimada K. Metastasizing ectopic thymoma arising in the right thoracic cavity and mimicking diffuse pleural mesothelioma: An autopsy study of a case with review of the literature. Wien Klin Wschr 1986, 98:14-20.
469. Shih D., Wang J., Tseng H., et al. Primary pleural thymoma. Arch Pathol Lab Med 1997, 121:79-82.
470. Gaertner E., Zeren H., Fleming M.V., et al. Biphasic synovial sarcomas arising in the pleural cavity: A clinicopathologic study of five cases. Am J Surg Pathol 1996, 20:36-45.
471. Nicholson A.G., Goldstraw P., Fischer C. Synovial sarcoma of the pleura and its differentiation from other primary pleural tumors: A clinicopathological and immunohistochemical review of three cases. Histopathol 1998, 33:508-513.
472. Colwell A.S., D'Cunha J., Vargas S.O., et al. Synovial sarcoma of the pleura: A clinical and pathologic study of three cases. J Thorac Cardiovasc Surg 2002, 124:828-832.
473. Yano M., Toyooka S., Tsukuda K., et al. SYT-SSX fusion genes in synovial sarcoma of the thorax. Lung Cancer 2004, 44:391-397.
474. Ordonez N.G., Mahfouz S.M., Mackay B. Synovial sarcoma: An immunohistochemical and ultrastructural study. Hum Pathol 1990, 21:733-749.
475. Litzky L.A. Pulmonary sarcomatous tumors. Arch Pathol Lab Med 2008, 132:1104-1117.
476. Hachitanda Y., Aoyama C., Sato J.K., et al. Pleuropulmonary blastoma in childhood. A tumor of divergent differentiation. Am J Surg Pathol 1993, 17:382-391.
477. Priest J.R., McDermott M.B., Bhatia S., et al. Pleuropulmonary blastoma: A clinicopathologic study of 50 cases. Cancer 1997, 80:147-161.
478. Hill D.A., Sadeghi S., Schultz M.Z., et al. Pleuropulmonary blastoma in an adult: An initial case report. Cancer 1999, 85:2368-2374.
479. Celikoglu F., Teirstein A.S., Krellenstein D.J., et al. Pleural effusion in non-Hodgkin's lymphoma. Chest 1992, 101:1357-1360.
480. Vega F., Padula A., Valbuena J.R., et al. Lymphomas involving the pleura: A clinicopathologic study of 34 cases diagnosed by pleural biopsy. Arch Pathol Lab Med 2006, 130:1497-1502.
481. Fetsch P.A., Abati A., Hijazi Y.M. Utility of the antibodies CA-19-9, HBME-1 and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer 1998, 84:101-108.
482. Khoor A., Whitsett J.A., Stahlman M.T., et al. Utility of surfactant protein B precursor and thyroid transcription factor-1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol 1999, 30:695-700.
483. Curry P.M., Butcher D.N., Fisher C., et al. Value of the mesothelium associated antibodies thrombomodulin, cytokeratin 5/6, calretinin and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol 2000, 13:107-112.
484. Ordonez N.G. Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma: Review and update. Am J Clin Pathol 1999, 112:75-89.
485. Ordonez N.G. Immunohistochemical diagnosis of epithelioid mesotheliomas: A critical review of old markers, new markers. Hum Pathol 2002, 33:953-967.
486. Ordonez N.G. The immunohistochemical diagnosis of mesothelioma: A comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003, 27:1031-1051.
487. Comin C.E., Novelli L., Boddi V., et al. Calretinin, thrombomodulin, CEA and CD15: A useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol 2001, 32:529-536.
488. Zhang P.J., Genega E.M., Tomaszewski J.E., et al. The role of calretinin, inhibin, melan-A, BCL-2 and C-kit in differentiating adrenal cortical and medullary tumors: An immunohistochemical study. Mod Pathol 2003, 16:591-597.
489. Laskin W.B., Miettinen M. Epithelioid sarcoma: New insights based on an extended immunohistochemical analysis. Arch Pathol Lab Med 2003, 127:1161-1168.
490. Pan C., Chen D.C., Choo T., et al. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. Hum Pathol 2003, 34:1155-1162.
491. Fine S.W., McClain S.A., Li M. Immunohistochemical staining for calretinin is useful for differentiating schwannomas from neurofibromas. Am J Clin Pathol 2004, 122:552-559.
492. Bergmann L., Maurer U., Weidmann E. Wilms tumor gene expression in acute myeloid leukemias. Leuk Lymphoma 1997, 25:435-443.
493. Sugiyama H. Wilms tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemia. Leuk Lymphoma 1998, 30:55-61.
494. Hwang H., Quenneville L., Yaziji H., et al. Wilms tumor gene product: Sensitive and contextually specific marker of serous carcinoma of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol 2004, 12:122-126.
495. Carpentieri D.F., Nichols K., Chou P.M., et al. The expression of WT-1 in the differentiation of rhabdomyosarcoma from other pediatric small round blue cell tumors. Mod Pathol 2002, 15:1080-1086.
496. Davidson B., Reich R., Lazarovici P., et al. Expression of the nerve growth factor receptor TrkA and p75 in malignant mesothelioma. Lung Cancer 2004, 44:159-165.
497. Hammar S.P., Bockus D.E., Remington F.L., et al. Mucin-positive epithelial mesotheliomas: A histochemical, immunohistochemical and ultrastructural comparison with mucin-producing pulmonary adenocarcinomas. Ultra Pathol 1996, 20:293-325.
498. Mayall F.G., Gibbs A.R. The histology and immunohistochemistry of small cell mesothelioma. Histopathology 1992, 20:47-51.
499. Mayall F.G., Jasani B., Gibbs A.R. Immunohistochemical positivity for neuron specific enolase and Leu 7 in malignant mesotheliomas. J Pathol 1992, 165:325-328.
500. Falconieri G., Zanconati F., Bussani R., et al. Small cell carcinoma of lung simulating mesothelioma. Pathol Res Pract 1995, 191:1147-1151.
501. van Hengel P., van Geffen F., Kazzaz B.A., et al. Atypical carcinoid presenting as mesothelioma. Neth J Med 2001, 58:185-190.
502. Henderson D.W., Atwood H.D., Constance T.J., et al. Lymphohistiocytoid mesothelioma: A rare lymphomatoid variant of predominantly sarcomatoid mesothelioma. Ultrastruct Pathol 1988, 12:367-384.
503. Daya D., McCaughey W.T.E. Well-differentiated papillary mesothelioma of the peritoneum: A clinicopathologic study of 22 cases. Cancer 1990, 65:292-296.
504. Yesner R., Hurwitz A. Localized pleural mesothelioma of epithelial type. J Thorac Surg 1953, 26:325-329.
505. Thickett D.R., Armstrong L., Millar A.B. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 1999, 54:707-710.
506. Golden A., Ash J. Adenomatoid tumors of genital tract. Am J Pathol 1990, 14:63-80.
507. Isotalo P.A., Keeney G.L., Sebo T.J., et al. Adenomatoid tumor of the adrenal gland: A clinicopathologic study of five cases and review of the literature. Am J Surg Pathol 2003, 27:969-977.
508. Overstreet K., Wixum C., Shabaik A., et al. Adenomatoid tumor of the pancreas: A case report with comparison of histology and aspiration cytology. Mod Pathol 2003, 16:613-617.
509. Argani P., Rosai J. Hyperplastic mesothelial cells in lymph nodes. Report of six cases of a benign process that simulate metastatic involvement by mesothelioma or carcinoma. Am J Surg Pathol 1998, 29:339-346.
510. Brooks J.S.J., LiVolsi V.A., Pietra G.G. Mesothelial cell inclusions in mediastinal lymph nodes mimicking metastatic carcinoma. Am J Clin Pathol 1990, 93:741-748.
511. Ordonez N.G., Ro J.Y., Ayal A.G. Lesions described as nodular mesothelial hyperplasia are primarily composed of histiocytes. Am J Surg Pathol 1998, 22:285-292.
512. Sussman J., Rosai J. Lymph node metastasis as the initial manifestation of malignant mesothelioma: Report of six cases. Am J Surg Pathol 1990, 14:819-828.
513. Kannerstein M., Churg J., McCaughey W.T.E., et al. Papillary tumors of the peritoneum in women: Mesothelioma or papillary carcinoma. Am J Obstet Gynecol 1977, 127:306-314.
514. Foyle A., Al-Jabi M., McCaughey W.T.E. Papillary peritoneal tumors in women. Am J Surg Pathol 1981, 5:241-249.
515. Mills S.E., Andersen W.A., Fechner R.E., et al. Serous surface papillary carcinomas: A clinicopathologic study of 10 cases and comparison with stage III-IV ovarian serous carcinoma. Am J Surg Pathol 1988, 12:827-834.
516. Raju U., Fine G., Greenwald K.A., et al. Primary papillary serous neoplasia of the peritoneum: A clinicopathologic and ultrastructural study of eight cases. Hum Pathol 1989, 20:426-436.
517. Bell D.A., Scully R.E. Benign and borderline serious lesions of the peritoneum in women. Pathol Annu 1989, 24(pt 2):1-21.
518. Rutledge M.L., Silva E.G., McLemore D., et al. Serous surface carcinoma of the ovary and peritoneum: A flow cytometric study. Pathol Annu 1989, 24(pt 2):227-235.
519. Bell D.A., Scully R.E. Serous borderline tumors of the peritoneum. Am J Surg Pathol 1990, 14:230-239.
520. Truong L.D., Maccato M.L., Awalt H., et al. Serous surface carcinoma of the peritoneum: A clinicopathologic study of 22 cases. Hum Pathol 1990, 21:99-110.
521. Shah I.A., Jayram L., Gani O.S., et al. Papillary serous carcinoma of the peritoneum in a man. Cancer 1998, 82:860-866.
522. Biscotti C.V., Hart W.R. Peritoneal serous micropapillomatosis of low malignant potential (serous borderline tumors of the peritoneum): A clinicopathologic study of 17 cases. Am J Surg Pathol 1992, 16:467-475.
523. Khoury N., Raju R., Crissman J.D., et al. A comparative immunohistochemical study of peritoneal and ovarian tumors, and mesotheliomas. Hum Pathol 1990, 21:811-819.
524. Taylor D.R., Page W., Huges D., et al. Metastatic renal cell carcinoma mimicking pleural mesothelioma. Thorax 1987, 42:901-902.
525. Ordonez N.G., Myhre M., Mackay B. Clear cell mesothelioma. Ultrastruct Pathol 1996, 20:331-336.
526. Butnor K.J., Nicholson A.G., Allred D.C., et al. Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. Arch Pathol Lab Med 2006, 130:823-827.
527. Illei P.B., Rusch V.W., Zakowski M.F., et al. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clinical Cancer Research 2003, 9:2108-2113.
528. Lopez-Rios F., Chuai S., Flores R., et al. Global gene expression profiling of pleural mesotheliomas: Overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Research 2006, 66:2970-2979.
529. Prins J.B., Williamson K.A., Kamp M.M., et al. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 1998, 75:649-653.
530. Xio S., Li D., Vijg J., et al. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995, 11:511-515.
531. Chiosea S., Krasinskas A., Cagle P.T., et al. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol 2008, 21:742-747.
532. Illei P.B., Ladanyi M., Rusch V.W., et al. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer 2003, 99:51-56.
533. Dacic S, Kothmaier H, Land S, et al. Prognostic significance of P16/CDKN2A loss in pleural malignant mesotheliomas. Virchows Archives (in press).
534. Allen T.C., Popper H.H., Kothmaier H., et al. Osteopontin (OPN) and HIF-1 expression in diffuse malignant mesothelioma (DMM) with long-term (>3 year) survival (LS) versus short-term survival (SS). Mod Pathol 2008, 21:335A.
535. Chung C.T.-S., Santos G.C., Hwang D.M., et al. p16/CDKN2A deletion as a diagnostic marker to distinguish benign from malignant mesothelial proliferations. Mod Pathol 2008, 21:338A.
536. Xu H., Simon R., Bourne P.A., et al. Immunohistochemical analysis of KOC/IMP3 in malignant pleural mesothelioma. Mod Pathol 2008, 21:353A.
537. Gardner J.M., Allen T.C., Jagirdar J., et al. Expression of matrix metalloproteinase-7 (MMP-7) in 45 diffuse malignant mesotheliomas (MM): Potential target for therapy. Mod Pathol 2008, 21:342A.
538. Moore B.H., Cagle P.T., Allen T.C., et al. Topoisomerasae II-alpha, minichromosome maintenance protein 2 (MCM2), and X-linked mammalian inhibitor of apoptosis protein (XIAP) expression in pleural diffuse malignant mesothelioma (PDMM): Possible role for chemotherapeutic intervention. Mod Pathol 2008, 21:347A.
539. Westerhoff M., Faoro L., Loganathan S., et al. Immunohistochemical (IHC) expression of c-Met receptor tyrosine kinase (c-Met) has prognostic significance and its activation is related to phosphorylated protein kinase Cβ (p-PKC β) in malignant mesothelioma (MM). Mod Pathol 2008, 21:353A.